Di Guardo Lorenza
Recenti Prog Med. 2022 Jun;113(6):28e-30e. doi: 10.1701/3827.38162.
Malignant melanoma is a malignant tumor with a poor prognosis. From 2010 the discovery of mutation of BRAF and the development of drugs against this target significantly improved the survival of these patients. The best results were achieved with the double inhibition of the MAPK pathway. There are 3 approved targeted therapies: vemurafenib and cobimetinib, dabrafenib and trametinib, encorafenib and binimetinib. They have similar efficacy, but different toxicity profiles. In this article, is critically review the case of a patient with metastatic melanoma treated with the combination encorafenib and binimetinib.
恶性黑色素瘤是一种预后较差的恶性肿瘤。自2010年BRAF突变被发现以及针对该靶点的药物研发以来，这些患者的生存率得到了显著提高。MAPK通路的双重抑制取得了最佳效果。有3种获批的靶向治疗药物：维莫非尼和考比替尼、达拉非尼和曲美替尼、恩考芬尼和比美替尼。它们具有相似的疗效，但毒性特征不同。在本文中，我们将严格审视一名接受恩考芬尼和比美替尼联合治疗的转移性黑色素瘤患者的病例。
